About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​

About ABPI Scotland

The ABPI represents innovative resea rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences across Scotland. Our industry, a major contributor to the economy, brings life-saving and life-enhancing medicines to patients. Across the UK, we represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease. Globally our industry is researching and developing more than 7,000 new medicines. The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.

​About the new ABPI Scotland Director Alison Culpan

Alison Culpan is the Director of ABPI Scotland and is responsible for leading government affairs activity for secretariat based in Edinburgh. For the past 35 years, Alison has worked in a number of capacities in the pharmaceutical industry in the UK including sales and marketing, project management, communication and external affairs. She gained global experience at GlaxoSmithKline as Director for Global Issues working with the World Health Organisation and the International Federation of Pharmaceutical Manufacturers & Associations. Alison sits on the CBI Scotland Council and the Court of Strathclyde University.

​About the Fraser of Allander Institute

The Fraser of Allander Institute at the University of Strathclyde is Scotland's leading independent research institute focussed upon the Scottish economy. The Institute undertakes a mix of cutting-edge academic research alongside detailed analysis and economic support for the private, public and third sectors. For more information on the Fraser of Allander Institute, visit www.strath.ac.uk/fraser

Notes to Editors

This report is supported by a series of case studies including:

  • Th​​e World's longest running collaboration between pharma and academia. 

    The University of Dundee's Division of Signal Transduction Therapy (DSTT) was awarded funding of £7.2 million in 2016 by international pharmaceutical companies Boehringer Ingelheim, GlaxoSmithKline (GSK) and Merck, continuing a partnership that will soon celebrate its 20th anniversary. The funding secures the posts of 38 scientists for four years, and will enable the DSTT to continue its research into a number of disease areas, including cancer, arthritis, lupus, hypertension and Parkinson's.

  • GlaxoSmithKline (GSK) / University of Edinburgh collaboration to treat acute pancreatitis

    GSK has chosen Edinburgh University for one of a small number of GSK Discovery Partnerships with Academia (DPAc). This programme focuses on an inflammatory mechanism in acute pancreatitis associated with the development of multiple organ failure – and developing this idea into a potential medicine. Under the DPAc agreement terms, the University of Edinburgh has been receiving milestone-based financial support from GSK to support their research, and will receive sales royalties from any medicine that is ultimately commercialised as a result of the collaboration.

  • Bristol-Myers Squibb (BMS) – investing in the University of Strathclyde

    BMS is part of the ADDoPT (Advanced Digital Design of Pharmaceutical Products) project, a £20 million programme funded by the Advances Manufacturing Supply Chain Initiative. ADDoPT aims to develop world-class modelling capabilities to the pharmaceutical industry and its regulators, for all aspects of pharmaceutical development.  A central part of this programme is the collaboration with the Institute of Pharmacy and Biomedical Sciences at the University of Strathclyde, who have world-leading capabilities in understanding the solid-state crystal form of medicines.

  • Roche – a global company investing in Scotland

    Roche invests heavily in Scotland to help in the delivery of global research efforts. In 2016, Roche spent a total of £132 million in Scotland with NHS Scotland, universities, research organisations and biotechnology companies.

  • The CMAC (Continuous Manufacturing and Advanced Crystallization) Future Manufacturing Research Hub

    CMAC's vision is to revolutionise the way pharmaceuticals and high value products are made. The approaches developed and adopted within CMAC have been developed through close collaboration with industry and the support of its Tier 1 partners, which includes GlaxoSmithKline, AstraZeneca, Bayer, Lilly, Novartis, Roche and Takeda. Established in 2011, the CMAC has a £150m funding portfolio and currently comprises more than 130 staff and researchers, including academics, post docs, and more than 45 PhD students, as well as an experienced support team.

  • Bristol-Myers Squibb (BMS) investing in research collaboration with Midlothian based pharma services company

    Since 2011, BMS and Midlothian based Solid Form Solutions have successfully collaborated on a number of projects to advance and understand BMS' products in the pipeline. This collaboration, which has already seen a six-figure investment, is expected to expand in the years to come. One aspect of this work is research relating to the "solid state" of the medicine substance.

  • MSD: US pharma company investing in Scottish R&D

    IOmet are based at the Edinburgh BioQuarter, one of Scotland's life science clusters of excellence, and their acquisition by MSD, reported to be £280 million, represented a major vote of confidence in the Scottish life sciences sector. The focus of their business is in the field of cancer immunotherapy, a way of harnessing the power of the body's own immune system to treat cancer.

Parliamentary Launch – Tuesday 28 November

The Fraser of Allander Institute report will be presented at the inaugural meeting of the Cross-Party Group for Life Sciences in the Scottish Parliament on Tuesday 28 November in the Livingstone Room at 18.00. Media are invited to send a representative. Please contact Visitor Services if not a Parliamentary passholder.​

Media enquiries


+44 (0) 20 7747 7147​​